Checked
Lymphoma Clinical Trials in Missouri
Open studies with at least one site in the state
Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.
- Open studies
- 59
- With a site in Missouri
- Most studies in
- St Louis
- 44 of the studies shown
Studies
50 of 59, recruiting studies first. Cities are where the study lists a Missouri site.
- Collection of Tissue Samples for Cancer ResearchRecruitingNCT00900198· National Cancer Institute (NCI)
St Louis
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingPhase 2NCT03739814· National Cancer Institute (NCI)
St Louis, Cape Girardeau, Joplin, Rolla and 12 more
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingPhase 2NCT04840602· National Cancer Institute (NCI)
St Louis, Cape Girardeau, City of Saint Peters, Creve Coeur and 1 more
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2NCT06124157· National Cancer Institute (NCI)
St Louis, Kansas City
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.RecruitingPhase 1, Phase 2NCT06697184· BeOne Medicines
St Louis
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2NCT06317662· National Cancer Institute (NCI)
St Louis, Kansas City
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsRecruitingPhase 3NCT06549595· AstraZeneca
Chesterfield, Springfield
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingPhase 2NCT06649812· National Cancer Institute (NCI)
St Louis, City of Saint Peters, Creve Coeur
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingPhase 3NCT06717347· Merck Sharp & Dohme LLC
Bridgeton, Kansas City, Springfield
- Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or AstrocytomaRecruitingPhase 1NCT06860594· National Cancer Institute (NCI)
St Louis, City of Saint Peters, Creve Coeur
- Testing the Effect of Teclistamab on Recurrent Plasmablastic LymphomaRecruitingPhase 1NCT07332507· National Cancer Institute (NCI)
St Louis, City of Saint Peters, Creve Coeur
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3NCT03150693· Alliance for Clinical Trials in Oncology
St Louis, Joplin, Rolla, Springfield and 7 more
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)RecruitingPhase 3NCT05303519· Nuvation Bio Inc.
St Louis
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingPhase 1NCT04301076· National Cancer Institute (NCI)
St Louis, City of Saint Peters, Creve Coeur
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesRecruitingPhase 1NCT06528301· Umoja Biopharma
St Louis
- Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLRecruitingPhase 2NCT06526793· AstraZeneca
St Louis
- A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesRecruitingNCT07154823· Tempus AI
St Louis
- An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersRecruitingNCT07226934· Washington University School of Medicine
St Louis
- Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsRecruitingNCT06418204· Wake Forest University Health Sciences
Kansas City, St Louis, Ballwin, Sainte Genevieve and 8 more
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 3NCT06084936· Hoffmann-La Roche
Chesterfield
- Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)RecruitingPhase 1, Phase 2NCT06395103· Merck Sharp & Dohme LLC
Kansas City
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingPhase 2NCT04803201· Alliance for Clinical Trials in Oncology
St Louis, Chesterfield, Creve Coeur, Springfield
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaRecruitingPhase 3NCT05976763· Alliance for Clinical Trials in Oncology
Kansas City, St Louis, Springfield, Cape Girardeau and 5 more
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLRecruitingPhase 2NCT06500273· Allogene Therapeutics
Columbia, Kansas City, Springfield, St Louis
- Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerRecruitingPhase 3NCT07215910· Alliance for Clinical Trials in Oncology
St Louis, Kansas City, City of Saint Peters, Creve Coeur and 2 more
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaRecruitingPhase 2NCT07015242· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
St Louis
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaRecruitingPhase 1NCT07192471· Kyowa Kirin, Inc.
St Louis
- NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell LymphomaRecruitingPhase 1NCT07052305· Washington University School of Medicine
St Louis
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)RecruitingPhase 3NCT06742996· BeOne Medicines
St Louis
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingPhase 1, Phase 2NCT04094610· Turning Point Therapeutics, Inc.
St Louis
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaRecruitingPhase 3NCT06561048· Corvus Pharmaceuticals, Inc.
St Louis
- Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial ChemotherapyRecruitingPhase 3NCT06724237· Eastern Cooperative Oncology Group
St Louis, Kansas City, City of Saint Peters, Creve Coeur and 1 more
- A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care MogamulizumabRecruitingNCT07003100· City of Hope Medical Center
St Louis
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaRecruitingPhase 1, Phase 2NCT04870944· Children's Oncology Group
Kansas City, St Louis
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1, Phase 2NCT06634589· BeOne Medicines
St Louis
- TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasRecruitingPhase 1NCT07082803· Treeline Biosciences, Inc.
St Louis
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2NCT04546399· National Cancer Institute (NCI)
St Louis, Kansas City
- CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantRecruitingPhase 2NCT06687772· Washington University School of Medicine
St Louis
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3NCT03959085· Children's Oncology Group
St Louis, Columbia, Kansas City
- Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use DisorderRecruitingPhase 2NCT06651177· T. John Winhusen, PhD
Cape Girardeau
- This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin LymphomaRecruitingPhase 1NCT07121946· LTZ Therapeutics, Inc.
St Louis
- DALY II USA/ MB-CART2019.1 for DLBCLRecruitingPhase 2NCT04792489· Miltenyi Biomedicine GmbH
St Louis
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)RecruitingNCT01351545· Center for International Blood and Marrow Transplant Research
St Louis, Kansas City
- A Registry for People With T-cell LymphomaRecruitingNCT05978141· Memorial Sloan Kettering Cancer Center
St Louis
- Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer TreatmentRecruitingNCT01790152· Children's Oncology Group
Columbia, St Louis
- Post-Op Pain Control for Prophylactic Intramedullary Nailing.RecruitingPhase 3NCT03823534· St. Louis University
St Louis
- BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaRecruitingPhase 2NCT06854003· Christine Ryan
St Louis
- Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S TrialRecruitingPhase 3NCT05006482· University of Rochester
Osage Beach
- Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)RecruitingPhase 2NCT06390956· University of Utah
St Louis
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1, Phase 2NCT05643742· CRISPR Therapeutics AG
St Louis
Other cancer studies in Missouri
Frequently asked questions
- Are there lymphoma clinical trials in Missouri?
- Yes. 59 lymphoma studies on ClinicalTrials.gov list at least one site in Missouri and are recruiting, about to recruit or enrolling by invitation, including sites in St Louis, Kansas City, Creve Coeur.
- What does recruiting mean?
- Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
- How do I join a clinical trial?
- Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.
Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/26/2026